Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma

Teeranachaideekul, Veerawat; Boonsongsawat, Worrawee; Asanawittaya, Waralee; Jintapattanakit, Anchalee; Chantasart, Doungdaw; Wongrakpanich, Amaraporn

Abstract

Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma

Author(s): Teeranachaideekul Veerawat, Boonsongsawat Worrawee, Asanawittaya Waralee, Jintapattanakit Anchalee, Chantasart Doungdaw, Wongrakpanich Amaraporn

Issue: Jan/Feb 2021 - Volume 25, Number 1

View All Articles in Issue

Page(s): 62-72

Download in electronic PDF format for $75

Abstract

Concentrated 7% w/w a-arbutin cream was formulated and evaluated using O/W and W/O emulsion bases as an extemporaneous preparation for melasma treatment. Cream bases were formulated with two pH values, 4.0 and 5.5, using a hot process. The stability of the creams was studied for 60 days under three storage conditions (i.e., 2°C to 8°C, 30°C, 40°C). Cream characteristics and all aspects of product stability including physical, chemical, and microbial were investigated. Stability was defined as no dramatic change in color, viscosity, pH, and no visible microbial growth. For stability, at least 90% of the initial a-arbutin concentration quantified by stability-indicating high-performance liquid chromatography must be obtained. It was found that pH had no influence on the a-arbutin or formulations’ stability. All formulations had a-arbutin remaining higher than 90% (approximately 92%) after being stored for 60 days in all storage conditions with no significant changes in pH or viscosity. All samples complied with the microbial limits test for nonsterile pharmaceutical preparation for cutaneous products. However, a color change was detected in O/W and W/O emulsions, especially at 40°C storage condition within 28 and 14 days, respectively. Drug crystals were observed in W/O emulsion stored at 2°C to 8°C. Concerning the in vitro drug release, a-arbutin was released from O/W emulsion but not from W/O emulsion. From the above results, the O/W emulsion that was developed in this study can be used as a cream base for concentrated a-arbutin as an extemporaneous preparation. The developed a-arbutin cream prepared using O/W emulsions can be used as an extemporaneous preparation with a beyond-use date of 60 days when stored at room temperature (30°C) and in the refrigerator (2°C to 8°C).

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jan/Feb 2021 Pg. 62-72	Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Author(s): Teeranachaideekul Veerawat, Boonsongsawat Worrawee, Asanawittaya Waralee, Jintapattanakit Anchalee, Chantasart Doungdaw, Wongrakpanich Amaraporn
Jul/Aug 2003 Pg. 266-270	Sensitization Therapy for Warts Author(s): Kuntz Rachael
Sep/Oct 2009 Pg. 386-389	Skin Disorders in Horses; Case Report: Tripelennamine in the Treatment of Skin Disorders in Horses Author(s): Williams LaVonn A, Fokken Dawn
Jul/Aug 2004 Pg. 269-274	Current Topical Treatments in Wound Healing - Part 1 Author(s): Helmke Christopher D
Nov/Dec 2014 Pg. 512-515	In Vitro Skin Penetration and Skin Content of Progesterone from Various Topical Formulations Author(s): Heustess Allie, Asbill Scott, Eagerton David, Arnold John
Jul/Aug 2014 Pg. 332-340	Evaluation of Percutaneous Absorption Performance for Human Female Sexual Steroids into Pentravan Cream Author(s): Polonini Hudson C, Brandão Marcos Antônio F, Ferreira Anderson O, Ramos Cristiano, Raposo Nádia R B
Jan/Feb 2022 Pg. 54	Deoxyarbutin 3% Anhydrous Emulsion Author(s): Allen Loyd V Jr
Jul/Aug 2003 Pg. 288-291	Basics of Compounding for Raynaud's Disease Author(s): Glasnapp Andrew
Nov/Dec 2003 Pg. 460-463 View Sample	Basics of Compounding for Dry-Skin Conditions Author(s): Allen Loyd V Jr
Nov/Dec 2018 Pg. 446-454	Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications Author(s): Zur Eyal
Nov/Dec 2020 Pg. 446-448	NASEM Report on Compounded Topical Pain Creams Author(s): Allen Loyd V Jr
Sep/Oct 2007 Pg. 425	Nondetergent Neutral Dry Skin Cream Author(s): Allen Loyd V Jr
Jan/Feb 2000 Pg. 72-75	Physicochemical Stability of Compounded Creams Containing alpha-Hydroxy Acids Author(s): de Villiers Melgardt M, Narsai Kirti, van der Watt Jakkie G
Sep/Oct 2015 Pg. 357-365	Novel Approaches to Topical Psoriasis Therapy Author(s): Koyama Gregory, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
Jul/Aug 2020 Pg. 320	Sumatriptan, Lidocaine Hydrochloride, Dexamethasone, Pentoxifylline, and Ibuprofen Transdermal Cream (Migraine Cream) Author(s): Allen Loyd V Jr
Jul/Aug 2002 Pg. 303-304	Topical Oil-in-Water Cream Bases, Featured Excipient: Author(s): Allen Loyd V Jr
Jul/Aug 2002 Pg. 255-256	Aminophylline 3%, Co-dergocrine Mesylate 0.05%, and Isosorbide Dinitrate 0.25% Cream for the Treatment of Orgasmic Dysfunction in Women Author(s): Mason Dave
Nov/Dec 2007 Pg. 505	Breast Care Cream Author(s): Allen Loyd V Jr
Jul/Aug 2021 Pg. 336-343	Compatibility of Estradiol, Estriol, Estrone, Progesterone, and Testosterone Single Formulation in Fitalite, Versatile, or HRT Supreme Cream Base Author(s): Polonini Hudson C, Dijkers Eli, Ferreira Anderson O, Zander Clark, Taylor Sarah
Sep/Oct 2016 Pg. 412	Progesterone 10% Cream Author(s): Allen Loyd V Jr